Can pretreatment hepatic artery perfusion scintigraphy in patients
with liver malignancies predict the treatment response of the
selective internal radiation therapy with 90Y resin microspheres?

guney, isa burak; ballı, hüseyin tuğsan; Ünal, İlker; Küçüker, Kadir Alper; KIBAR, MUSTAFA

doi:10.5152/dir.2022.20775

Can pretreatment hepatic artery perfusion scintigraphy in patients with liver malignancies predict the treatment response of the selective internal radiation therapy with 90Y resin microspheres?

İsa Burak GÜNEY, (Çukurova Üniversitesi, Tıp Fakültesi, Nükleer Tıp Bölümleri, Adana, Türkiye)

Hüseyin Tuğsan BALLI, (Çukurova Üniversitesi, Tıp Fakültesi, Nükleer Tıp Bölümleri, Adana, Türkiye)

Kadir Alper KÜÇÜKER, (Çukurova Üniversitesi, Tıp Fakültesi, Nükleer Tıp Bölümleri, Adana, Türkiye)

İlker ÜNAL, (Çukurova Üniversitesi, Tıp Fakültesi, Nükleer Tıp Bölümleri, Adana, Türkiye)

Mustafa KİBAR (Çukurova Üniversitesi, Tıp Fakültesi, Nükleer Tıp Bölümleri, Adana, Türkiye)

Diagnostic and Interventional Radiology

1 1

Yıl: 2022 Cilt: 28 Sayı: 2 Sayfa Aralığı: 156 - 165 Metin Dili: İngilizce DOI: 10.5152/dir.2022.20775 İndeks Tarihi: 23-06-2022

Can pretreatment hepatic artery perfusion scintigraphy in patients with liver malignancies predict the treatment response of the selective internal radiation therapy with 90Y resin microspheres?

Öz:

We aimed to evaluate whether the perfusion pattern from pretreatment hepatic artery perfusion scintigraphy (HAPS) in patients with liver malignancies can predict response to selective internal radiation therapy (SIRT). METHODS This retrospective study analyzed 152 consecutive patients treated with yttrium-90 (90Y) resin microspheres between April 2015 and July 2017. HAPS using single-photon emission computed tomography/computed tomography (SPECT/CT) with 99mtechnetium macroaggregated albumin (99mTc-MAA) was performed before SIRT. Investigators visually classified perfusion patterns of tumors as heterogeneous or diffuse in HAPS. Between diffuse and heterogeneous pattern group, positron emission tomography/computed tomography (PET/CT) andmagnetic resonance imaging (MRI) were performed in third and sixth month after SIRT, and tumor response assessed and compared by using RECIST 1.1 ormRECIST. Overall survival (OS) and progression-free survival (PFS) were also compared with Kaplan-Meier/log-rank analyses. RESULTS Of 216 SIRT procedures, 172 were classified as heterogeneous and 44 as diffuse. Diffuse 99mTc- MAA uptake was associated with longer median OS than heterogeneous (22.2 vs. 14.4 months, respectively; P = .047). Subsegmental infusion was associated with longer OS than either lobar or segmental infusion (P = .090). Mean estimated OS was longer in patients with hepatocellular carcinoma (HCC) (34.2 months) than with colorectal carcinoma (CRC) (16.4 months) (P = .044). Patients with both diffuse and heterogeneous patterns were able to show complete response after SIRT. No statistically significant differences were observed between perfusion patterns and PFS or response rates to SIRT. CONCLUSION Although tumor perfusion patterns from preplanning HAPS analyses are useful for estimating tumor uptake of 90Y, they may not reliably predict hepatic treatment response, as patients with different perfusion patterns can show clinical response to SIRT.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Saxena A, Chua TC, Bester L, Kokandi A, Morris DL. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: A critical appraisal of 48 cases. Ann Surg. 2010;251(5):910-916. [Crossref]
2. Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): A combined analysis of three multicentre, randomised, Phase 3 trials. Lancet Oncol. 2017;18 (9):1159-1171. [Crossref] a b c d Figure 4. a-d. Patient case: A 59-year-old woman with colorectal cancer in segment 2. (a) 18F-FDG PET/CT demonstrates dense FDG uptake in a peripheral rim and a central necrotic ametabolic area (arrow). (b) 3-month follow-up 18F-FDG PET/CT image shows completemetabolic response. (c) HAPS SPECT/CT fusion images acquired before SIRT showing a heterogeneous perfusion pattern in ametastatic lesion in segment 2with linearMAA uptake in segment 4A (thick arrow) but faintMAA uptake in the center of the tumor (thin arrow). (d) Bremsstrahlung image acquired after SIRT does not show linear MAA uptake in segment 4A but shows high microsphere distribution in the center of the tumor (thin arrow). 164 • February 2022 • Diagnostic and Interventional Radiology Guney
3. Kennedy A. Radioembolization of hepatic tumors. J Gastrointest Oncol. 2014;5(3):178-189. 4. Sangro B, Inarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol. 2012;56(2):464-473. [Crossref]
5. Gong C, Ma G, Hu X, et al. Pretreatment 18F-FDG uptake heterogeneity predicts treatment outcome of first-line chemotherapy in patients with metastatic triple-negative breast cancer. Oncologist. 2018;23(10):1144-1152. [Crossref]
6. Li XF, Du Y, Ma Y, Postel GC, Civelek AC. 18FFluorodeoxyglucose Uptake and Tumor Hypoxia: Revisit 18F-Fluorodeoxyglucose in Oncology Application. Transl Oncol. 2014;7(2):240-247. [Crossref]
7. Civelek AC, Sitzmann JV, Chin BB, Venbrux A, Wagner HNJr, Grochow LB. Misperfusion of the liver during hepatic artery infusion chemotherapy: Value of preoperative angiography and postoperative pump scintigraphy. AJR Am J Roentgenol. 1993;160(4):865-870. [Crossref]
8. Padia SA, Lewandowski RJ, Johnson GE, et al. Radioembolization of hepatic malignancies: Background, quality improvement guidelines, and future directions. J Vasc Interv Radiol. 2017;28(1):1-15. [Crossref]
9. Lenoir L, Edeline J, Rolland Y, et al. Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization. Eur J Nucl Med Mol Imaging. 2012;39(5):872-880. [Crossref]
10. Lambert B, Mertens J, Sturm EJ, Stienaers S, Defreyne L, D’Asseler Y. 99mTc-labelled macroaggregated albumin (MAA) scintigraphy for planning treatment with 90Y microspheres. Eur J Nucl Med Mol Imaging. 2010;37(12):2328- 2333. [Crossref]
11. Hamami ME, Poeppel TD, Muller S, et al. SPECT/ CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer. J Nucl Med. 2009;50(5):688-692. [Crossref]
12. Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: The MIRD equations for dose calculations. J Nucl Med. 2006;47(7):1209- 1211.
13. Flamen P, Vanderlinden B, Delatte P, et al. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with yttrium-90 labeled resin microspheres. Phys Med Biol. 2008;53(22):6591-6603. [Crossref]
14. Ulrich G, Dudeck O, Furth C, et al. Predictive value of intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-microspheres. J Nucl Med. 2013;54 (4):516-522. [Crossref]
15. Volkan-Salanci B, Bozkurt MF, Peynircioglu B, Cil B, Ugur O. The relation between perfusion pattern of hepatic artery perfusion scintigraphy and response to y-90 microsphere therapy. Mol Imaging Radionucl Ther. 2013;22(3):98-102. [Crossref]
16. Haug AR, Heinemann V, Bruns CJ, et al. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. Eur J Nucl Med Mol Imaging. 2011;38(6):1037-1045. [Crossref]
17. Sabet A, Ahmadzadehfar H, Muckle M, et al. Significance of oral administration of sodium perchlorate in planning liver-directed radioembolization. J Nucl Med. 2011;52(7):1063-1067. [Crossref]
18. LauWY, Kennedy AS, KimYH, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys. 2012;82(1):401-407. [Crossref]
19. Kao YH, Tan EH, Ng CE, Goh SW. Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: A technical review. Ann Nucl Med. 2011;25 (7):455-461. [Crossref]
20. Gaba RC, Lewandowski RJ, Hickey R, et al. Transcatheter therapy for hepatic malignancy: Standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2016;27(4):457-473. [Crossref]
21. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET study group. Eur J Cancer. 1999; 35(13):1773- 1782. .[Crossref]
22. Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): An open-label randomised controlled phase 3 trial. Lancet Oncol. 2017; 18(12):1624-1636. [Crossref]
23. Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: Selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913- 1921. [Crossref]
24. Edeline J, Crouzet L, Campillo-Gimenez B, et al. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. Eur J Nucl Med Mol Imaging. 2016;43(4):635-643. [Crossref]
25. Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: Multicenter radiology- pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60(1):192-201. [Crossref]
26. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: Chemoembolization versus radioembol ization. Am J Transplant. 2009;9(8):1920-1928. [Crossref]
27. Braat AJ, Huijbregts JE, Molenaar IQ, Borel Rinkes IH, Van Den Bosch MA, Lam MG. Hepatic radioembolization as a bridge to liver surgery. Front Oncol. 2014;4:199. [Crossref]
28. Zhao Y, Liu C, Zhang Y, et al. Prognostic value of tumor heterogeneity on 18F-FDG PET/CT in HR+HER2- metastatic breast cancer patients receiving 500 mg fulvestrant: A retrospective study. Sci Rep. 2018;8 (1):14458. [Crossref]
29. Senthilnathan S, Memon K, Lewandowski RJ, et al. Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: Analyzing patterns of progression in 285 patients. Hepatology. 2012;55(5):1432-1442. [Crossref]

APA	guney i, ballı h, Küçüker K, Ünal İ, KIBAR M (2022). Can pretreatment hepatic artery perfusion scintigraphy in patients with liver malignancies predict the treatment response of the selective internal radiation therapy with 90Y resin microspheres?. , 156 - 165. 10.5152/dir.2022.20775
Chicago	guney isa burak,ballı hüseyin tuğsan,Küçüker Kadir Alper,Ünal İlker,KIBAR MUSTAFA Can pretreatment hepatic artery perfusion scintigraphy in patients with liver malignancies predict the treatment response of the selective internal radiation therapy with 90Y resin microspheres?. (2022): 156 - 165. 10.5152/dir.2022.20775
MLA	guney isa burak,ballı hüseyin tuğsan,Küçüker Kadir Alper,Ünal İlker,KIBAR MUSTAFA Can pretreatment hepatic artery perfusion scintigraphy in patients with liver malignancies predict the treatment response of the selective internal radiation therapy with 90Y resin microspheres?. , 2022, ss.156 - 165. 10.5152/dir.2022.20775
AMA	guney i,ballı h,Küçüker K,Ünal İ,KIBAR M Can pretreatment hepatic artery perfusion scintigraphy in patients with liver malignancies predict the treatment response of the selective internal radiation therapy with 90Y resin microspheres?. . 2022; 156 - 165. 10.5152/dir.2022.20775
Vancouver	guney i,ballı h,Küçüker K,Ünal İ,KIBAR M Can pretreatment hepatic artery perfusion scintigraphy in patients with liver malignancies predict the treatment response of the selective internal radiation therapy with 90Y resin microspheres?. . 2022; 156 - 165. 10.5152/dir.2022.20775
IEEE	guney i,ballı h,Küçüker K,Ünal İ,KIBAR M "Can pretreatment hepatic artery perfusion scintigraphy in patients with liver malignancies predict the treatment response of the selective internal radiation therapy with 90Y resin microspheres?." , ss.156 - 165, 2022. 10.5152/dir.2022.20775
ISNAD	guney, isa burak vd. "Can pretreatment hepatic artery perfusion scintigraphy in patients with liver malignancies predict the treatment response of the selective internal radiation therapy with 90Y resin microspheres?". (2022), 156-165. https://doi.org/10.5152/dir.2022.20775

APA	guney i, ballı h, Küçüker K, Ünal İ, KIBAR M (2022). Can pretreatment hepatic artery perfusion scintigraphy in patients with liver malignancies predict the treatment response of the selective internal radiation therapy with 90Y resin microspheres?. Diagnostic and Interventional Radiology, 28(2), 156 - 165. 10.5152/dir.2022.20775
Chicago	guney isa burak,ballı hüseyin tuğsan,Küçüker Kadir Alper,Ünal İlker,KIBAR MUSTAFA Can pretreatment hepatic artery perfusion scintigraphy in patients with liver malignancies predict the treatment response of the selective internal radiation therapy with 90Y resin microspheres?. Diagnostic and Interventional Radiology 28, no.2 (2022): 156 - 165. 10.5152/dir.2022.20775
MLA	guney isa burak,ballı hüseyin tuğsan,Küçüker Kadir Alper,Ünal İlker,KIBAR MUSTAFA Can pretreatment hepatic artery perfusion scintigraphy in patients with liver malignancies predict the treatment response of the selective internal radiation therapy with 90Y resin microspheres?. Diagnostic and Interventional Radiology, vol.28, no.2, 2022, ss.156 - 165. 10.5152/dir.2022.20775
AMA	guney i,ballı h,Küçüker K,Ünal İ,KIBAR M Can pretreatment hepatic artery perfusion scintigraphy in patients with liver malignancies predict the treatment response of the selective internal radiation therapy with 90Y resin microspheres?. Diagnostic and Interventional Radiology. 2022; 28(2): 156 - 165. 10.5152/dir.2022.20775
Vancouver	guney i,ballı h,Küçüker K,Ünal İ,KIBAR M Can pretreatment hepatic artery perfusion scintigraphy in patients with liver malignancies predict the treatment response of the selective internal radiation therapy with 90Y resin microspheres?. Diagnostic and Interventional Radiology. 2022; 28(2): 156 - 165. 10.5152/dir.2022.20775
IEEE	guney i,ballı h,Küçüker K,Ünal İ,KIBAR M "Can pretreatment hepatic artery perfusion scintigraphy in patients with liver malignancies predict the treatment response of the selective internal radiation therapy with 90Y resin microspheres?." Diagnostic and Interventional Radiology, 28, ss.156 - 165, 2022. 10.5152/dir.2022.20775
ISNAD	guney, isa burak vd. "Can pretreatment hepatic artery perfusion scintigraphy in patients with liver malignancies predict the treatment response of the selective internal radiation therapy with 90Y resin microspheres?". Diagnostic and Interventional Radiology 28/2 (2022), 156-165. https://doi.org/10.5152/dir.2022.20775